The Preclinical Therapeutics Core (Core) provides in vivo services to UCSF Helen Diller Family Comprehensive Cancer Center (Center) investigators. Offering a variety of tumor engraftment-based cancer models for use in preclinical oncology trials, the Core provides a complete set of services that include consultation regarding experimental design, tumor cell culture and implantation in mice, administration of experimental agents, monitoring of tumor burden and response to therapy, and interpretation of study results. The Core maintains a cryorepository of commonly used human cancer cell lines derived from multiple tumor types along with data regarding their in vivo growth characteristics, as well as a collection of patient-derived tumor xenograft models. The Core's offerings also include pharmacological analysis and optimization of novel agents such as compound formulation, pharmacokinetics (PK), pharmacodynamics (PD), and safety-toxicity analyses. The Core is also a resource of expertise in small animal survival surgery, and is available to provide training in these techniques on a recharge basis. Although the Core primarily functions to test experimental anti-cancer agents in vivo, it also provides animal models of human cancer for use in novel diagnostic, tumor imaging, and basic mechanistic research. The Core oversees, maintains, and provides as a service a number of small animal imaging technologies housed within the barrier facility. The availability of centralized cell and animal resources, together with personnel with expertise in conducting preclinical studies, ensures appropriate experimental design and reproducibility, compliance with local and federal regulatory guidelines for tumor-bearing animals, and maximum resource utilization through coordinated animal purchasing and housing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693947
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$263,196
Indirect Cost
$96,533
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Chen, Justin; Weiss, William A (2014) When deletions gain functions: commandeering epigenetic mechanisms. Cancer Cell 26:160-1
Johnson, Brett E; Mazor, Tali; Hong, Chibo et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-93
Witte, John S; Visscher, Peter M; Wray, Naomi R (2014) The contribution of genetic variants to disease depends on the ruler. Nat Rev Genet 15:765-76
Sufiawati, Irna; Tugizov, Sharof M (2014) HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread. PLoS One 9:e88803
Sharma, Vineeta; Witkowski, Andrzej; Witkowska, H Ewa et al. (2014) Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291). Arterioscler Thromb Vasc Biol 34:2254-60
Gustafson, William Clay; Meyerowitz, Justin Gabriel; Nekritz, Erin A et al. (2014) Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26:414-27
Gable, Jonathan E; Lee, Gregory M; Jaishankar, Priyadarshini et al. (2014) Broad-spectrum allosteric inhibition of herpesvirus proteases. Biochemistry 53:4648-60
Cope, Leslie M; Fackler, Mary Jo; Lopez-Bujanda, Zoila et al. (2014) Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS One 9:e105545
Bankoti, Jaishree; Apeltsin, Leonard; Hauser, Stephen L et al. (2014) In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 75:266-76
Ilkanizadeh, Shirin; Lau, Jasmine; Huang, Miller et al. (2014) Glial progenitors as targets for transformation in glioma. Adv Cancer Res 121:1-65

Showing the most recent 10 out of 71 publications